Clinical contribution of tumor marker CYFRA 21-1 in evaluation of response to therapy in NSCLC patients Source: Eur Respir J 2001; 18: Suppl. 33, 377s Year: 2001
The diagnostic value of the examination of the tumor markers CYFRA 21-1, NSE, TPA and CEA from the bronchoalveolar lavage fluid in diffuse pulmonary disorders Source: Annual Congress 2008 - Role of bronchoalveolar lavage in studying the pathophysiology of interstitial lung disease Year: 2008
Biodynamic approach to pretreatment level of tumor marker CYFRA 21-1 in differential diagnosis of single pulmonary nodules Source: Annual Congress 2003 - Early lung cancer diagnosis Year: 2003
Clinical significance of CEA, NSE, CYFRA 21-1 in serum and pleural fluid for the diagnosis of malignant pleural effusion associated with primary lung cancer Source: Eur Respir J 2004; 24: Suppl. 48, 528s Year: 2004
Diagnostic utility of CYFRA 21-1 and carcinoembryonic antigen as a tumour markers in malignant pleural effusions Source: Eur Respir J 2001; 18: Suppl. 33, 397s Year: 2001
Prognostic significance of three tumor markers (CA125, CEA, and TPA) in lung cancer Source: Eur Respir J 2002; 20: Suppl. 38, 73s Year: 2002
Tumor markers (TM) CEA, CYFRA 21-1,MCA and NSE in pleural effusion(PE) at malignant mezothelioma and metastatic tumor of pleura Source: Eur Respir J 2002; 20: Suppl. 38, 439s Year: 2002
Post operative dynamism of NSCLC tumor markers (CEA, CYFRA 21.1, NSE, TK, TPS) Source: Eur Respir J 2006; 28: Suppl. 50, 719s Year: 2006
Response to cancer chemotherapy (CTh) in patients (pts) with non-small cell lung cancer (NSCLC) according to their serum levels of chosen tumor markers (CYFRA 21-1 (CY21), CEA and NSE) Source: Eur Respir J 2001; 18: Suppl. 33, 377s Year: 2001
Serum carcinoembryonic antigen (CEA) level as a predictive marker for distant metastasis in non-small cell lung cancer Source: Eur Respir J 2006; 28: Suppl. 50, 85s Year: 2006
Diagnostic value of linear combination of CYFRA 21-1 and carcinoembryonic antigen in malignant pleural effusions Source: Eur Respir J 2004; 24: Suppl. 48, 528s Year: 2004
Prognostic and predictive value of cytokeratin-19 fragments (Cyfra 21-1), carcinoembryonic antigen (CEA) and human chorionic gonadotropin (bHCG) in 138 NSCLC patients - 5 years of observation Source: Eur Respir J 2002; 20: Suppl. 38, 73s Year: 2002
Neuron-specific enolase (NSE) serum level as a prognostic factor for tumor regression and survival in non-small cell lung cancer (NSCLC) Source: Eur Respir J 2002; 20: Suppl. 38, 73s Year: 2002
Usefulness of determination of tumour markers TPA and cyfra 21.1 in follow up study after radical therapy in patients with nonsmall cell lung cancer (NSCLC) Source: Eur Respir J 2001; 18: Suppl. 33, 377s Year: 2001
Can high levels of serum tumor markers be useful in predicting the histologic type of lung cancer? Source: Eur Respir J 2004; 24: Suppl. 48, 77s Year: 2004
Smoking status and serum NSE, as prognostic factors in adenocarcinoma of lung Source: Eur Respir J 2005; 26: Suppl. 49, 325s Year: 2005
Evaluation of serum tumour markers in the lung cancer patients Source: Eur Respir J 2002; 20: Suppl. 38, 268s Year: 2002
An elevated serum level of cyfra 21 heralds poor outcome for operable bronchogenic cancer Source: Eur Respir J 2004; 24: Suppl. 48, 40s Year: 2004
CEA levels in the serum and induced sputum of lung cancer patients Source: Eur Respir J 2005; 26: Suppl. 49, 324s Year: 2005
The diagnostic value of serum tumor markers in newly diagnosed lung cancer patients Source: International Congress 2017 – Lung cancer - clinical research: scientific pearls from the bedside Year: 2017